Unresectable advanced hepatocellular carcinoma research hub

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

This study looks at a new drug, CS1003, combined with an existing treatment, Lenvatinib, for people with advanced liver cancer that can't be removed by surgery. Researchers want to see if this combination helps people live longer compared to Lenvatinib alone.